BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 19, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Sanegene Bio’s SGB-3908 cleared to enter clinic in China for hypertension
To read the full story,
subscribe
or
sign in
.
Cardiovascular
Sanegene Bio’s SGB-3908 cleared to enter clinic in China for hypertension
May 8, 2024
No Comments
Suzhou Sanegene Bio Inc.’s clinical trial application for SGB-3908 injection, an siRNA drug for the treatment of hypertension, has been accepted in China by the National Medical Products Administration (NMPA)’s Center for Drug Evaluation (CDE).
BioWorld Science
Regulatory
Cardiovascular
China
NMPA